Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR3 S249C |
Therapy | Erdafitinib + Quisinostat |
Indication/Tumor Type | urinary bladder cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 S249C | urinary bladder cancer | sensitive | Erdafitinib + Quisinostat | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Balversa (erdafitinib) and Quisinostat (JNJ-26481585) synergistically inhibited viability in a bladder cancer cell line harboring FGFR3 S249C in culture (PMID: 37479885). | 37479885 |
PubMed Id | Reference Title | Details |
---|---|---|
(37479885) | Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy. | Full reference... |